<scp>TP53</scp> Mutation Is the Only Robust Mutational Biomarker for Outcome Found in a Consecutive Clinical Cohort of Real‐Word Patients With Primary Large B‐Cell Lymphoma
With a targeted gene panel and NGS methodology feasible in daily diagnostic routine, we identified high-risk gene mutations with a significant prognostic impact of which TP53 mutations were reproducible across validation cohorts.
Authors
- Lars Møller Pedersen (ORCID: https://orcid.org/0000-0002-9419-8841)
- Anne Ortved Gang (ORCID: https://orcid.org/0000-0003-0160-1257)
- Lone Schejbel (ORCID: https://orcid.org/0000-0003-3677-3227)
- Estrid Høgdall (ORCID: https://orcid.org/0000-0003-4689-5658)
- Torsten Holm Nielsen (ORCID: https://orcid.org/0009-0000-7309-3859)
- Ib Jarle Christensen (ORCID: https://orcid.org/0000-0002-3017-7195)
- Marie Fredslund Breinholt (ORCID: https://orcid.org/0000-0002-1204-4807)
- Peter Nørgaard (ORCID: https://orcid.org/0009-0004-0241-1951)
Institutions
- University of Copenhagen (DK)
- Danish Medicines Agency (DK)
- Hvidovre Hospital (DK)
- Gentofte Hospital (DK)
- Rigshospitalet (DK)
- Zealand University Hospital (DK)
Publication Details
- Journal
- European Journal Of Haematology
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1111/ejh.14364
- Citations
- 1
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.42